

For Immediate Release
April 2006

Contact:

Joanne Walsh
Heritage Partners Intl
203/789-0000
JWalsh@HeritageLeaders.com

Heritage Partners International assists Curagen Corporation to recruit Dr. Frank Armstrong as President and Chief Executive Officer.

Curagen Corporation and New Haven based Heritage Partners International recently announced the appointment of Dr. Frank Armstrong to the position of President and Chief Executive Officer.

Dr. Armstrong comes to CuraGen Corporation with more than twenty years of experience obtained at major pharmaceutical companies, including Bayer AG and Zeneca Pharmaceuticals, and in the biotechnology sector. Throughout his career, Dr. Armstrong has successfully led the worldwide development, regulatory approval and commercialization of drugs across a variety of therapeutic areas including oncology, anti-infectives, and antipsychotics.

Dr. Armstrong has held roles of increasing responsibility including Senior Vice President Medical Research and Communications Group at Zeneca Pharmaceuticals (now AstraZeneca) from May 1985 through May 1998, and was Head of Worldwide Product Development for Bayer AG from May 1998 to December 2001. Throughout his tenure in the pharmaceutical industry, Dr. Armstrong has led the commercialization and launch of numerous drug products worldwide. Dr. Armstrong has also assisted in strategic portfolio management, fostered business development through partnering and licensing activities, led the lifecycle management of marketed products, been responsible for all aspects of patient and drug safety and pharmacovigilance, and played an integral role in the development of sales and marketing strategies.

During the past four years Dr. Armstrong has applied his considerable skills at smaller technology and biotechnology companies where he successfully raised capital, licensed products and advanced pipelines. Dr. Armstrong was Chief

Executive Officer of Phoqus, a private drug delivery company, Chief Executive Officer of Provensis, a company developing treatments for varicose veins, and most recently Chief Executive Officer of Bioaccelerate, a drug development company utilizing a novel business model for the acquisition and advancement of potential drug candidates. All three companies were U.K. based. Dr. Armstrong was appointed to the CuraGen Board of Directors in 2005, and will continue to serve as a member and will become a Member of the Board of 454 Life Sciences, a majority owned subsidiary of CuraGen. Dr Armstrong will continue to serve on the Board of Directors of Avidex, Ltd, Oxford, UK.

Dr. Armstrong holds degrees in Biochemistry and Medicine from the University of Edinburgh in Scotland, is an elected Fellow of the Royal College of Physicians and an elected Fellow of the Faculty of Pharmaceutical Medicine.

“Dr. Armstrong’s recruitment was the result of a solid team effort between Curagen’s Board of Directors and our group here at Heritage Partners. The board set the standard exceptionally high and Dr. Armstrong definitely met all of the requirements. He is an outstanding choice”, noted Managing Partner Kevin Butler.

Heritage Partners International (HPI) is a senior level executive search firm that focuses on delivering superior work to a select group of clients globally in the Life Sciences Industry (www.HeritageLeaders.com). The firm was founded by several senior consultants who had previously held leadership positions with the large, general practice firms including Heidrick & Struggles, Spencer Stuart and Russell Reynolds. In addition, our partners have held senior positions at leading pharmaceutical and biotechnology companies in the United States and Europe.

HPI works in partnership with Whitehead Mann, a leading European based executive search and consulting firm, to provide global services to its clients.